References
1. Maitland-van der Zee, A.H., A. de Boer, and H.G. Leufkens, The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol, 2000. 410 (2-3): p. 121-130.
2. Abrahams, E., Right drug-right patient-right time: personalized medicine coalition. Clin Transl Sci, 2008. 1 (1): p. 11-2.
3. Lazarou, J., B.H. Pomeranz, and P.N. Corey, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998. 279 (15): p. 1200-5.
4. Evans, W.E. and H.L. McLeod, Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med, 2003.348 (6): p. 538-49.
5. Prado, M.S., K. Bendtzen, and L.E.C. Andrade, Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. Expert Opin Drug Metab Toxicol, 2017. 13 (9): p. 985-995.
6. Gomez, A. and M. Ingelman-Sundberg, Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther, 2009. 85 (4): p. 426-30.
7. Choi, J.R., et al., Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy. Cancer Res Treat, 2015. 47 (3): p. 509-17.
8. Hoehndorf, R., M. Dumontier, and G.V. Gkoutos, Identifying aberrant pathways through integrated analysis of knowledge in pharmacogenomics. Bioinformatics, 2012. 28 (16): p. 2169-75.
9. Tozzi, V., R. Libertone, and G. Liuzzi, HIV pharmacogenetics in clinical practice: recent achievements and future challenges. Curr HIV Res, 2008. 6 (6): p. 544-54.
10. Harper, A.R. and E.J. Topol, Pharmacogenomics in clinical practice and drug development. Nat Biotechnol, 2012. 30 (11): p. 1117-24.
11. Phillips, K.A., et al., Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA, 2001.286 (18): p. 2270-9.
12. Pouget, J.G., et al., Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci, 2014. 16 (4): p. 555-66.
13. Flowers, C.R. and D. Veenstra, The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics, 2004.22 (8): p. 481-93.
14. Savage, D.R., U.S. Food, and A. Drug, FDA guidance on pharmacogenomics data submission. Nat Rev Drug Discov, 2003.2 (12): p. 937-8.
15. Davies, S.M., Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet? ASH Education Program Book, 2006. 2006 (1): p. 111-117.
16. Leong, S.L., et al., Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: A systematic review and meta-analysis of genotypes effect. International journal of cardiology, 2019. 280 : p. 190-197.
17. Lowitt, M.H. and N.H. Shear, Pharmacogenomics and dermatological therapeutics. Archives of dermatology, 2001.137 (11): p. 1512-1514.
18. Cavallari, L.H., J. Shin, and M.A. Perera, Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011. 31 (12): p. 1192-1207.
19. Lunshof, J.E. and D. Gurwitz, Pharmacogenomic testing: knowing more, doing better. Clin Pharmacol Ther, 2012. 91 (3): p. 387-9.
20. Wadelius, M. and A. Alfirevic, Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing . 2011, Springer.
21. Shah, J., Criteria influencing the clinical uptake of pharmacogenomic strategies. BMJ, 2004. 328 (7454): p. 1482-6.
22. Overby, C.L., et al., Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. BMC Bioinformatics, 2010. 11 Suppl 9 : p. S10.
23. Altar, C.A., et al., Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J, 2015. 15 (5): p. 443-51.
24. Benitez, J., et al., The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes. Appl Transl Genom, 2015. 5 : p. 47-9.
25. Carlberg, C., The need for education in personalized medicine. Personalized medicine, 2012. 9 (2): p. 147-150.
26. Zachary III, W. and E.P. Armstrong, Health care professionals’ perceptions of the role of pharmacogenomic data. Journal of Managed Care Pharmacy, 2002. 8 (4): p. 278-284.
27. Tranter, B. and S. Noble, Communication in oncology pharmacy: The challenge of treatment adherence. Oxford Textbook of Communication in Oncology and Palliative Care, 2017: p. 328.
28. K Zgheib, N., F. Ghaddar, and R. Sabra, Teaching pharmacogenetics in low and middle-income countries: team based learning and lessons learned at the American University of Beirut. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), 2011. 9 (1): p. 25-40.
29. Elewa, H., et al., A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Qatar. J Eval Clin Pract, 2015. 21 (4): p. 703-9.
30. AlEjielat, R., et al., An evaluation of the knowledge, opinions, expectations and concerns toward pharmacogenomics among Jordanian pharmacists. Personalized medicine, 2016. 13 (2): p. 143-154.
31. Muzoriana, N., et al., Knowledge, attitude, and perceptions of pharmacists and pharmacy students towards pharmacogenomics in Zimbabwe.Pharmacy, 2017. 5 (3): p. 36.
32. Perwitasari, D., et al., Knowledge, Awareness and Attitude of Pharmacists toward Pharmacogenetic Practice: Perspective of Community and Hospital in Yogyakarta, Indonesia. J Community Med Health Educ, 2017. 7 (568): p. 2161-0711.1000568.
33. Abdela, O.A., et al., Ethiopian health care professionals’ knowledge, attitude, and interests toward pharmacogenomics.Pharmacogenomics and personalized medicine, 2017. 10 : p. 279.
34. Albassam, A., et al., Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait.PloS one, 2018. 13 (9).
35. Offit, K., Personalized medicine: new genomics, old lessons.Human genetics, 2011. 130 (1): p. 3-14.
36. Xie, B., D.M. Dilts, and M. Shor, The physician–patient relationship: the impact of patient‐obtained medical information.Health economics, 2006. 15 (8): p. 813-833.
37. Arathy, R., J. Chacko, and S. Pillai, A knowledge, attitude, and practices study of pharmacogenomics and its educational needs among doctors in a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 2019. 9 (2): p. 99-102.
38. Collins, F.S., M. Morgan, and A. Patrinos, The Human Genome Project: lessons from large-scale biology. Science, 2003.300 (5617): p. 286-90.
39. Jarrar, Y., Perception of primary care physicians’ toward pharmacogenetics in Jordan. Jordan Med J, 2019. 53 (3): p. 81-89.
40. Gallipani, A., et al., Prescriber Attitudes Toward Implementation of Pharmacogenomic Testing in a Family Medicine Residency Program. PRiMER, 2018. 2 .
41. Bonter, K., et al., Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine.BMJ open, 2011. 1 (1): p. e000110.
42. Hui, C.H. and H.C. Triandis, Effects of culture and response format on extreme response style. Journal of Cross-Cultural Psychology, 1989.
43. NO, T.D.H., Arab Cultural Awareness: 58 Factsheets. 2006.